Back to top

Hutchmed announces China NMPA approval for Orpathys NDA

Hutchmed (HCM) announced that the new drug application, or NDA, for Orpathys has been granted conditional approval by the China National Medical Pr...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

HUTCHMED (China) Limited Sponsored ADR (HCM)